+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Thrombosis Drugs Market - Segmented by Drug Class, Disease type, Distribution Channel, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4622418
  • Report
  • August 2018
  • Region: Global
  • 117 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer Inc.
  • MORE
Thrombosis Drugs Market Overview

The Thrombosis Drugs Market is expected to register a CAGR of about 9.0% over the forecast period. Thrombosis is a major source of morbidity and mortality among elderly patients. It has been established that thrombosis is caused due to certain cardiovascular disorders as a result of old age or obesity. In the current era, there is an increasing burden of geriatric population along with obesity due to sedentary lifestyle across developed and emerging markets which is primarily associated to drive the thrombosis drugs business. As per the regional analysis, North America is expected to retain dominance owing to pivotal factors such as early adoption of new technologies, increasing burden of cardiovascular diseases and geriatric population, and good regulatory framework contributing to the growth of this market.

Growing Geriatric and Obese Population Boosts the Thrombosis Drugs Market

As per a publication of 2018 in the United States Census Bureau the population of people aged 65 and above in the US would increase drastically between 2016 and 2060 period. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million. Also, according to the National Health and Nutrition Examination Survey (NHANES) conducted in 2013–2014 one in every three adults were considered overweight, and about one in thirteen adults were suffering from extreme obesity. The increasing burden of obesity has also changed significantly in past one decade, globally. Both developed and emerging markets are having significant issues in controlling the associated diseases. The growing consumption of alcohol and tobacco with overweight and obesity adds a high risk of developing significant high blood pressure on veins for a large period of life leading to several thrombosis related complications, thus driving this market.
Other factors contributing to the growth of this market are increasing the burden of cardiovascular and trauma cases with increasing R&D expenditure in the field of hematological disorders.

Side-Effects Caused Due to Thrombosis Drugs to Impede the Growth of Thrombosis Drugs Market

Ideally, anti-clotting medication should not stop blood from clotting completely, this is because if the blood does not clot it might lead to major blood loss in case of injuries. When under treatment by anti-clotting medication a patient’s blood takes much longer to clot such as in case of any accidental cuts. Uncontrolled bleeding is a very common side effect of thrombolytic drugs. Another noteworthy side effect of anticoagulants is a stroke. In some rare scenarios heparins as well as clopidogrel can drastically lower blood platelets count in patients. Few drugs can affect the efficacy of anticlotting medication that in turn escalates the danger of complications. Coumarins have a particularly high amount of interactions with other drugs that comprises of OTC (over the counter) drugs. These side effects of thrombosis drugs often demand alternative therapy recommended by physicians and doctors to the patients. Thus, it is among the major barrier for the growth of this market over the forecast period.
Another factor that will impede market growth is lack of awareness about the severity of thrombosis.

North America to Retain Dominance in the Thrombosis Drugs Market

North America expected to retain dominance in this market with an estimated share of about half of the total market share in 2017. North America leads the market owing to the high prevalence of cardiovascular diseases, the upsurge in the demand for progressive treatment options and an increase in the elderly population. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and rise in collaboration of domestic and international companies with campaigns growing awareness in these countries, thus driving this market.

Key Developments in the Market
  • Aug, 2018: The US FDA the priority review of ALXN 1210, by Alexion Pharmaceuticals, Inc., for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Reasons to Purchase the Report
  • Current and future thrombosis drugs market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
  • This report can be customized to meet the patient’s requirements. Please connect with our representative, who will ensure the patient to get a report that suits the patient’s needs.
Note: Product cover images may vary from those shown
2 of 4


  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer Inc.
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Market Dynamics
6.1 Drivers
6.1.1 Growing Geriatric and Obese Population
6.1.2 Increasing Burden of Cardiovascular and Trauma Cases
6.1.3 Increasing Technological Advancements in Hematology
6.2 Restraints
6.2.1 Lack of Awareness about Venous Thromboembolism Conditions
6.2.2 Side-Effects Caused Due to Thrombosis Drugs
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Drug Class
7.1.1 Factor Xa Inhibitor
7.1.2 Heparin
7.1.3 P2Y12 Platelet Inhibitor
7.1.4 Others
7.2 By Disease Type
7.2.1 Pulmonary Embolism
7.2.2 Atrial Fibrillation
7.2.3 Deep Vein Thrombosis
7.2.4 Others
7.3 By Distribution Channel
7.3.1 Hospital Pharmacies
7.3.2 Retail Pharmacies
7.3.3 Online Pharmacies
7.4 By Geography
7.4.1 North America US Canada Mexico
7.4.2 Europe France Germany UK Italy Spain Rest of Europe
7.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
7.4.4 Middle East & Africa GCC South Africa Rest of MEA
7.4.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Aspen Pharmacare Holdings Limited
9.2 AstraZeneca PLC
9.2 Bayer AG
9.4 Boehringer Ingelheim GmbH
9.5 Bristol-Myers Squibb
9.6 Johnson & Johnson
9.7 Pfizer, Inc
9.8 Sanofi
* List Not Exhaustive

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi
Note: Product cover images may vary from those shown